Posts for Ticker ‘FOLD’

Top Day Trader Alerts (FOLD, BRCD, COF, FITB, SCLN, TRID, WFC)

These are this morning’s top day trader alerts and active trader alert stocks for Monday.  We have more details on volume and price analysis on each stock covered at VSInvestor.com:

Amicus Therapeutics (NASDAQ: FOLD) is hitting 52-week lows on its type 1 Gaucher disease treatment disappointment.

Brocade Communications Systems, Inc. (NASDAQ: BRCD) is trading up over 13% after the company has reportedly up for sale.

Capital One Financial Corp. (NYSE: COF) and Fifth Third Bancorp (NASDAQ: FITB) are both higher despite Goldman Sachs dropping FITB in favor of COF for its Conviction Buy List.

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) is down 7% but not as bad as it could have been after dropping its Phase 2 trial evaluating RP101 for late-stage pancreatic cancer.

Trident Microsystems Inc. (NASDAQ: TRID) is surging on higher guidance and an NXP combination of their digital TV and Set-Top box businesses.

Wells Fargo & Co. (NYSE: WFC) is up over 4% on the Goldman Sachs upgrade.

You can join our open email distribution list which goes out several times per week for reminders of the top day trader alerts, analyst upgrades and downgrades, IPO’s, key secondary offerings, guru investor data on Buffett and others, mergers, and more.

JON C. OGG
October 5, 2009

Posted on: October 5, 2009 – 9:10 am in After-Hours Activity, Pre-Market Activity, Trading Alert, , , , , , ,

Top Analyst Downgrades (AMD, FOLD, AMAG, FITB, PLCM, TIVO)

These are this Monday morning’s top early-bird analyst downgrades or cautious research calls from Wall Street firms:

Advanced Micro Devices (AMD) Cut to Market Perform at FBR.
Amicus Therapeutics (FOLD) Cut to Neutral at JPMorgan
AMAG Pharmaceuticals (AMAG) Cut to Hold at Jefferies.
Fifth Third Bancorp (FITB) Cut to Buy from Conviction Buy List at Goldman Sachs.
Polycom (PLCM) Cut to Market Perform at Wells Fargo.
TiVo (TIVO) Started as Neutral at JPMorgan.

You can join our open email distribution list which goes out several times per week for top day trader alerts, analyst upgrades and downgrades, IPO’s, key secondary offerings, guru investor data on Buffett and others, mergers, and more.

JON C. OGG

Posted on: October 5, 2009 – 7:17 am in Analyst Calls, , , , , ,

Biotech Business Daily (RIGL, BIIB, ARRY, ALNY, FOLD, HALO, AOB, STEM)

Here are some of the top stories affecting key drug and biotech stocks that have links through to more in-depth coverage and analysis today at the website BioHealthInvestor.com:

Rigel Pharmaceuticals Inc.’s (NASDAQ: RIGL) Phase IIb trial results Thursday morning of its rheumatoid arthritis candidate R788, is boosting its stock on speculation it may help the company attract a clinical partner.

Biogen Idec Inc. (NASDAQ: BIIB) is enjoying a second day of gains after its new PEGylated interferon beta-1a (BIIB017) for relapsing multiple sclerosis (RMS) received an FDA Fast Track designation.  This might be a game-changing event for the company with some risks as well.

Array BioPharma Inc. (Nasdaq: ARRY) now says it will discontinue development of ARRY-797 in chronic inflammatory diseases. Attention may now turn to Array’s ARRY-162, another anti-inflammatory that showed much more promising efficacy.

Also, see our in-depth feature this week on five fast-growing biotechs with improving analyst estimates: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM).

-The 24/7 Wall St. Team

Posted on: July 9, 2009 – 11:09 am in Biotech, Drug companies, FDA, Medical, , , , , , , ,

BioHealth Business Daily (CI, AET, MYL, JAZZ, PTIE, GSK, ALNY, FOLD, HALO, AOB, STEM)

Here are some of the top stories affecting key drug and biotech stocks that are covered in-depth today at BioHealthInvestor.com:

Cigna corp. (NYSE: CI), Aetna Inc. (NYSE: AET), and other managed care companies are rising despite making health care reform concessions, as shareholders see they have a seat at the bargaining table.

Mylan Inc. (NASDAQ: MYL) has received FDA approval for a generic version of an AstraZeneca (AZN) prostate cancer drug — a rather unusual new generic.

Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ) shares are up more than 25 percent after the company took steps to ease a cash crunch that had curtailed drug development.

King Pharmaceuticals (KG) and Pain Therapeutics (PTIE) said  they expect to resubmit a new drug application in mid-2010, slightly later than anticipated.

GlaxoSmithKline (NYSE: GSK) announced a positive study on its Cervarix vaccine, although it’s unclear if the company can play catch-up to Merck & Co.’s (NYSE: MRK) Gardasil.

See our in-depth feature this week on five fast-growing biotechs with improving analyst estimates: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM).

-The 24/7 Wall St. Team

Posted on: July 7, 2009 – 11:03 am in Biotech, Drug companies, FDA, Medical, Trading Alert, , , , , , , , , , ,

The Five Growth Biotech Names To Watch Right Now

biotechAlnylam (Nasdaq: ALNY) leads a short list of some of the fastest-growing biotech stocks
where analyst estimate revisions continue to rise.

BioHealth Investor began by analyzing 171 stocks in the biotech sector based on revenue growth over the trailing four quarters, identifying 30 stocks in the sector with better
than 50 percent revenue growth over the past 12 months.

We then screened those 30 stocks to look for those very few names that have seen both strong growth in at least the past two years and positive analyst estimate revisions in recent months, in an effort to find stocks with strong trends that still have potentially improving operations going forward.

The work resulted in growth biotech stocks to watch: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM). Read More »

Posted on: July 6, 2009 – 4:27 am in Biotech, , , , ,

Can Carl Icahn Fix Broken Biotechs? (ANX, BIIB, ENZN, IMCL, TELK, FOLD, AMLN, REGN)

Carl Icahn is a billionaire financier, activist, and investor.  Most think of Icahn as an activist investor that wants to get inside and drive value without having to acquire the whole company to resell it later.  This strategy works and works well, so long as the right strategies and efforts are applied properly to each stock.  The underlying sector a company is in is critical too, and for some reason Carl Icahn has been trying to do this in biotech stocks.  We took the biotech filings from both Mr. Icahn’s own holdings and from Icahn Capital LP to see what Mr. Icahn thinks he has up his sleeves.

CARL ICAHN direct holdings, via several investment vehicles:

Adventrx Pharmaceuticals Inc. (AMEX: ANX) down 80% from highs

  • $467,000.00 for 864,865 shares

Biogen-Idec (NASDAQ: BIIB) down about 25% from highs 

  • $153.4M for 2,487,181 shares

Enzon Pharmaceuticals (NASDAQ: ENZN) down only 16% from highs

  • $5.6M for 614,420 shares

ImClone Systems (NASDAQ: IMCL) down 18% from highs

  • $494.9M for 11,669,544 shares

Telik Inc. (NASDAQ: TELK) down over 50% from highs

  • $2.536M for 1,039,165 shares

ICAHN CAPITAL LP direct holdings:

Adventrx Pharmaceuticals Inc. (AMEX: ANX) down 80% from highs

  • $1.8M for 3,459,459 shares

Amicus Therapeutics, Inc. (NASDAQ: FOLD) down 45% from highs

  • $2.16M for 201,940 shares

Amylin Pharmaceuticals Inc. (AMLN) down 40% from highs

  • $185.1M for 6,339,653 shares

APPLERA (NYSE: ABI) down 10% from highs

  • $21.3M for 649,026 shares

Biogen-Idec (NASDAQ: BIIB) down about 25% from highs 

  • $613.7M for 9,948,723 shares

Enzon Pharmaceuticals (NASDAQ: ENZN) down only 16% from highs

  • $22.6M for 2,457,683 shares

Regenron Pharmaceuticals (NASDAQ: REGN) down about 28% from highs

  • $48.1M for 2,508,001 shares

Telik Inc. (NASDAQ: TELK) down over 50% from highs

  • $10.1M for 4,156,663 shares

*** percentage down from highs means the 52-week highs, so many are off much more than all-time or historical highs.

It may not be fair to refer to all of these as broken, because many aren’t.  What is interesting here is that if you follow biotech stocks and if you know these companies, most of these have fallen from their former glory.

Here is the problem with biotech stocks: They almost HAVE to be public to live up to expectations, so they very rarely go private because of the need for capital.  The mere nature of putting molecules and modified products into your body has risks, and many companies cannot control what happens or how people their meds after a while.  Biotech companies cannot control the FDA and they cannot control independent verification or investigative studies.  No company can control whether or not a competitor comes out with a greater product.  Biotechs are different in that investors would rather see a biotech spend cash to acquire another biotech rather than engage in a share buyback or pay out a dividend.  When was the last time you heard a broker or an investor discuss the high dividend check they expect from their biotech?  Me neither…

Mr. Icahn has a great track record of influencing companies.  He made a fortune off the move in Time Warner.  Motorola has so far been a flop and Yahoo! is just getting started.  But he didn’t become a billionaire by throwing darts nor by investing in mutual funds. 

But there is a real discourse here from biotechs to other sectors, and it would just seem much easier for Mr. Icahn to get better returns elsewhere.  It might be easier backing high-risk and high-reward biotech ventures from scratch instead of trying to fix existing biotechs with problems.

You can join our open email distribution list to hear about activist investing, special financings, M&A, IPO’s, secondary offerings, and other special situations.

Jon C. Ogg
May 16, 2008

Posted on: May 16, 2008 – 10:43 am in Biotech, , , , , , , ,

Biotech Movers & Shakers (FOLD, BAX, CYTK, DSCO, HALO, IMCL, SGEN)

Amicus Therapeutics (NASDAQ: FOLD) had a late afternoon surge, up 7% to $10.73. The 52 week range is $9.00 to $18.22.

Baxter International (NYSE: BAX)—contaminant in recalled Heparin identified by the FDA today. Shares rose slightly to $58.18 in response to board approved $2 billion stock buyback program. maybe it’s a major drug stock, but this has been a pending issue for some time.

Cytokinetics Inc. (NASDAQ: CYTK) up almost 10% to $3.38 today; annual report filed last week.

Discovery Laboratories Inc. (NASDAQ: DSCO) up over 10% today to $2.38 on a late afternoon rise on no new news.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) up 23% today to $6.06 on heavy late afternoon trading volume and no news. Halozyme dipped earlier this week due to downgrades.

ImClone Systems (NASDAQ: IMCL) showed little response to upgrades in anticipation to cancer clinical trial data. Shares inched up $0.20 to $43.30.

Seattle Genetics Inc. (NASDAQ: SGEN) upgraded by RBC Capital Markets and noted for strong research platform. Up 4% to $8.70. The 52-week range is $7.20 to $3.44.

Rachel Lopez
March 19, 2008

Posted on: March 19, 2008 – 3:56 pm in Biotech, , , , , , ,

The 52-Week Low Club (C)(MBI)(RAD)

Rite Aid Corporation (RAD) Ugly earnings. No turnaround here. Falls to $2.71 from 52-week high of $6.74.

MBIA (MBI) Concerns about CDOs being insured here. Falls to $18.84 from 52-week high of $76.02.

SLM (SLM) Still falling after comments about tough 2008 and possible dividend cut. Down to $19.84 from 52-week high of $58.

Altus Pharmaceuticals (ALTU) Partnership with Genentech (DNA) broken off. Sells off to $4.80 from 52-week high of $20.50.

Amicus Therapeutics (FOLD) Wall St. views new drug as less than competitive to current offerings. Shares drop to $9.20 from 52-week high of $18.22.

Array Biopharma (ARRY) Clinical trial fails. Drops to $7.81 from 52-week high of $14.59

Citigroup (C) Fresh concerns about mortgage risks. Drops to $29.34 from 52-week high of $57.

Douglas A. McIntyre

Douglas A. McIntyre

Posted on: December 20, 2007 – 4:03 pm in HI/LOW, , , , , , ,